p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53

Biochemical and Biophysical Research Communications

Volumn 347, Issue 1, 2006, Pages 60-66

  Hayashi, Syunji ^a,b   Ozaki, Toshinori ^a   Yoshida, Kaori ^a   Hosoda, Mitsuchika ^a   Todo, Satoru ^b   Akiyama, Shin ichi ^c   Nakagawara, Akira ^a  

^a CHIBA CANCER CENTER   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cisplatin; KB 3 1; MDM2; p53; p73

Indexed keywords

CISPLATIN; PROTEIN MDM2; PROTEIN P73;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33745745435     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.095     Document Type: Article

References (33)

1. Prives C., and Hall P.A. The p53 pathway. J. Pathol. 187 (1999) 112-126
2. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
3. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
4. Kubbutat M.H.G., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
5. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 (1997) 25-27
6. Hamilton T.C., O'Dwyer P.J., and Ozols R.F. Platinum analogues in preclinical and clinical development. Curr. Opin. Oncol. 5 (1993) 1010-1016
7. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
8. Lowe S.W. Cancer therapy and p53. Curr. Opin. Oncol. 7 (1995) 547-553
9. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., and Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig. 104 (1999) 263-269
10. Soussi T., and Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1 (2001) 233-240
11. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
12. Ikawa S., Nakagawara A., and Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 6 (1999) 1154-1161
13. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
14. Melino G., De Laurenzi V., and Vousden K.H. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2 (2002) 605-615
15. Ozaki T., and Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci. 96 (2005) 729-737
16. Stiewe T., Zimmermann S., Frilling A., Esche H., and Putzer B.M. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 62 (2002) 3598-3602
17. Pozniak C.D., Radinovic S., Yang A., McKeon F., Kaplan D.R., and Miller F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289 (2000) 304-306
18. Grob T.J., Novak U., Maisse C., Barcaroli D., Luthi A.U., Pimia F., Hugli B., Graber H.U., De L.V., Fey M.F., Melino G., and Tobler A. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8 (2001) 1213-1223
19. Nakagawa T., Takahashi M., Ozaki T., Watanabe K., Todo S., Mizuguchi H., Hayakawa T., and Nakagawara A. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol. Cell. Biol. 22 (2002) 2575-2585
20. Flores E.R., Tsai K.Y., Crowley D., Senqupta S., Yang A., McKeon F., and Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
21. Vikhanskaya F., D'Incalci M., and Broggini M. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res. 28 (2000) 513-519
22. Vikhanskaya F., Marchini S., Marabese M., Galliera E., and Broggini M. p73α overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res. 61 (2001) 35-938
23. Fujii R., Mutoh M., Niwa K., Yamada K., Aikou T., Nakagawa M., Kuwano M., and Akiyama S. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn. J. Cancer Res. 85 (1994) 426-433
24. Fujii R., Mutoh M., Sumizawa T., Chen Z., Yoshimura A., and Akiyama S. Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma cells. J. Natl. Cancer Inst. 86 (1994) 1781-1785
25. Miro-Mur F., Meiller A., Haddada H., and May E. p73α expression induces both accumulation and activation of wt-p53 independent of the p73α transcriptional activity. Oncogene 22 (2003) 5451-5456
26. Komatsu M., Sumizawa T., Mutoh M., Chen Z.-C., Terada K., Furukawa T., Yang X.-L., Gao H., Miura N., Sugiyama T., and Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 60 (2000) 1312-1316
27. Cocker H.A., Hobbs S.M., Tiffin N., Pritchard-Jones K., Pinkerton C.R., and Kelland L.R. High levels of the MDM2 oncoprotein in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br. J. Cancer 85 (2001) 1746-1752
28. Kool M., De Haas M., Scheffer G.L., Van Eijk M.J.T., Juijn J.A., Baas F., and Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57 (1997) 3537-3547
29. Rodicker F., and Putzer B.M. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res. 63 (2003) 2737-2741
30. Zhao H., and Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 21 (2001) 4129-4139
31. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268 (2001) 2764-2772
32. Wang X.-Q., Ongkeko W.M., Lau A.W.S., Leung K.M., and Poon R.Y.C. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 61 (2001) 1598-1603
33. Yu Y., Sun P., Sun L.C., Liu G.Y., Chen G.H., Shang L.H., Wu H.B., Hu J., Li Y., Mao Y.L., Sui G.J., and Sun X.W. Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin. Biochem. Biophys. Res. Commun. 339 (2006) 71-78